Journal of Cystic Fibrosis
Volume 4, Issue 2 , Pages 77-87 , May 2005

Immunisation in the current management of cystic fibrosis patients

Parts of this manuscript have been presented at the 25th European Cystic Fibrosis Conference in Genoa (Italy) in 2002

  • Anne Malfroot

      Affiliations

    • Department of Paediatrics, Paediatric Respiratory Medicine, Infectious Diseases and Cystic Fibrosis Clinic, Academisch Ziekenhuis-Vrije Universiteit Brussel (AZ-VUB), Laarbeeklaan 101, B-1090 Brussels, Belgium
    • Corresponding Author InformationCorresponding author. Tel.: +32 2 477 57 65; fax: +32 2 477 57 35.
    • ,
  • Georgios Adam

      Affiliations

    • Cystic Fibrosis Department, Aghia Sophia Childrens Hospital, Athens, Greece
    • ,
  • Oana Ciofu

      Affiliations

    • Institute for Medical Microbiology and Immunology, University of Copenhagen, Denmark
    • ,
  • Gerd Döring

      Affiliations

    • Institute of General and Environmental Hygiene, University of Tübingen, Germany
    • ,
  • Christiane Knoop

      Affiliations

    • Department of Pulmonology, Hôpital Universitaire ULB Erasme, Brussels, Belgium
    • ,
  • Aloïs B. Lang

      Affiliations

    • Department of Immunology, Berna Biotech, Bern, Switzerland
    • ,
  • Pierre Van Damme

      Affiliations

    • Division of Epidemiology and Community Medicine, Centre for the Evaluation of Vaccination, WHO Collaborating Centre for Prevention and Control of Viral Hepatitis University of Antwerp (UIA), Antwerp, Belgium
    • ,
  • Isi Dab

      Affiliations

    • Department of Paediatrics, Paediatric Respiratory Medicine, Infectious Diseases and Cystic Fibrosis Clinic, Academisch Ziekenhuis-Vrije Universiteit Brussel (AZ-VUB), Laarbeeklaan 101, B-1090 Brussels, Belgium
    • ,
  • Andrew Bush

      Affiliations

    • Department of Paediatrics, Royal Brompton Hospital, London, UK
    • ,
  • for the European Cystic Fibrosis Society (ECFS) Vaccination Group

Received 3 March 2004 ,Accepted 29 October 2004.

References 

  1. Yankaskas JR, Marshall BC, Sufian B, Simon RH, Rodman D. Cystic fibrisos adult care. Consensus conference report. Chest. 2004;125:1S–39S
  2. Orenstein DM, Winnie GB, Altman H. Cystic fibrosis: a 2002 update. J Pediatr. 2002;140:156–164
  3. Burroughs M, Moscona A. Immunisation of pediatric solid organ transplant candidates and recipients. Clin Infect Dis. 2000;30:857–869
  4. Webb NJ, Fitzpatrick MM, Hughes DA, Brocklebank TJ, Judd BA, Lewis MA, et al. Immunisation against varicella in end stage and pre-end stage renal failure. Arch Dis Child. 2000;88:141–143
  5. Giacchino R, Timitilli A, Castellano E, Di Rocco M, Fiore P, Sonconi R, et al. Hepatitis A vaccine in pediatric patients affected by metabolic liver diseases. Pediatr Infect Dis J. 2001;20:805–807
  6. van der Meer H, Kimpen JL. Insufficient vaccination status of children with a chronic disease. Ned Tijdschr Geneeskd. 1996;140:1402–1406
  7. Williams WW, Hickson MA, Kane MA, Kendal AP, Spika JS, Hinman AR. Immunisation policies and vaccine coverage among adults. The risk for missed opportunities. Ann Intern Med. 1988;108:616–625
  8. De Serres G, Shadmani R, Duval B, Boulianne N, Déry P, Douville Fradet M, et al. Morbidity of pertussis in adolescents and adults. J Infect Dis. 2000;182:174–179
  9. Birkebaek NH, Kristiansen M, Seefeldt T, Degn J, Moller A, Heron I, et al. Bordetella pertussis and chronic cough in adults. Clin Infect Dis. 1999;29:1239–1242
  10. Miller E, Vurdien J, Farrington P. Shift in age in chickenpox. Lancet. 1993;341:308–309
  11. De Schutter I, Malfroot A, Dab I, Hoebrekx N, Muyldermans G, Pierard D, et al. Molecular typing of Bordetella pertussis isolated recovered from Belgian children and their household members. Clin Infect Dis. 2003;36:1391–1396
  12. Elliman DA, Bedford HE. MMR vaccine-worries are not justified. Arch Dis Child. 2001;85:271–274
  13. Helwig H, et al. on behalf of the Confideration of European Specialists In Paediatrics (CESP) Childhood immunisation in the European Union. Eur J Pediatr. 1998;157:676–680
  14. Schmitt HJ, Booy R, Weil-Olivier C, Van Damme P, Cohen R, Peltola H. Child vaccination policies in Europe: a report from the Summits of Independent European Vaccination Experts. Lancet Infect Dis. 2003;3:103–108
  15. Kasper WJ, Howe PM. Fatal varicella after a single course of corticosteroids. Pediatr Infect Dis J. 1990;9:729–730
  16. Lang AB, Ruedeberg A, Schoeni MH, Que JU, Fuerer E, Schaad UB. Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection. Pediatr Infect Dis J. 2004;23:504–510
  17. Hadler SC. Global impact of hepatitis A virus infection: changing patterns. In:  Hollinger FB,  Lemon SM,  Margolis H editor. Viral hepatitis and liver disease. Baltimore: Williams & Wilkins; 1991;p. 14–20
  18. Akriviadis EA, Redeker AG. Fulminant hepatitis A in intravenous drug users with a chronic liver disease. Ann Intern Med. 1989;110:838–839
  19. Williams I, Bell B, Kaluba J, Shapiro C. Association between chronic liver disease and death from hepatitis A, United States, 1989–92 (abstract). In: IXth International Symposium on Viral Hepatitis, Rome. 1996;p. A39
  20. Lee SD, Chan CY, Yu MI, Wang YJ, Chang FY, Lo KJ, et al. Safety and immunogenicity of inactivated hepatitis A vaccine in patients with chronic liver disease. J Med Virol. 1997;52:215–218
  21. Keeffe EB, Iwarson S, McMahon BJ, Lindsay K, Koff RS, Manns M, et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology. 1998;27:881–886
  22. Michielsen PP, Van Damme P. Hepatitis vaccination in patients with chronic liver disease. Acta Gastro-Enterol. Belg. 2000;63:1–4
  23. Bell BP. Hepatitis A and hepatitis B vaccination of patients with chronic liver disease. Acta Gastro-Enterol. Belg. 2000;63:359–363
  24. Van Damme P. Hepatitis B: vaccination programmes in Europe—an update. Vaccine. 2001;19:2375–2379
  25. Van Damme P, Vorsters A. Hepatitis B control in Europe by universal vaccination programmes: the situation in 2001. J Med Virol. 2002;67:262–264
  26. Ling SC, Wilkinson JD, Hollman AS, McColl J, Evans TJ, Paton JY. The evolution of liver disease in cystic fibrosis. Arch Dis Child. 1999;81:129–132
  27. Wilschanski M, Rivlin J, Cohen S, Augarten A, Blau H, Aviram M, et al. Clinical and genetic risk factors for cystic fibrosis-related liver disease. Pediatrics. 1999;103:53–57
  28. Potter CJ, Fishbein M, Hammond S, McCoy K, Qualman S. Can the histologic changes of cystic fibrosis-associated hepatobiliary disease be predicted by clinical criteria?. J Pediatr Gastroenterol Nutr. 1997;25:32–36
  29. Neglia JP, et al. for the Cystic Fibrosis and Cancer Study Group The risk of cancer among patients with cystic fibrosis. N Engl J Med. 1995;332:494–499
  30. Van Damme P, Leroux-Roels G, Law B, Diaz-Mitoma F, Desombere I, Collard F, et al. Long-term persistence of antibodies induced by vaccination and safety follow-up, with the first combined vaccine against hepatitis A and B in children and adults. J Med Virol. 2001;65:6–13
  31. Van Der Wielen M, Van Damme P, Collard F. A two dose schedule for combined hepatitis A and hepatitis B vaccination in children ages one to eleven years. Pediatr Infect Dis J. 2000;19:848–853
  32. Centers for Disease Control and Prevention . Prevention of hepatitis A through active or passive immunisation: recommendations of the Advisory Committee on Immunization Practice (ACIP). MMWR. 1996;445(RR-15):1–30
  33. Craig AS, Schaffner W. Prevention of hepatitis A with the hepatitis A vaccine. N Engl J Med. 2004;350:476–481
  34. Glismann S, Ronne T, Schmitt JE. The EUVAC-NET survey: national measles surveillance systems in EU, Switzerland, Norway and Iceland. Eurosurveillance. 2001;6:105–110
  35. Vitek CR, Aduddell M, Brinton MJ, Hoffman RE, Redd SC. Increased protections during a measles outbreak of children previously vaccinated with a second dose of measles-mumps-rubella. Pediatr Infect Dis J. 1999;18:620–623
  36. American Academy of Pediatrics Committee on Infectious Diseases . Immunization of adolescents: recommendations of the Advisory Committee on Immunization Practices, the American Academy of Pediatrics, the American Academy of Family Physicians, and the American Medical Association. Pediatrics. 1997;99:479–488
  37. American Academy of Pediatrics . Age for routine second administration of the second dose of measles-mumps-rubella vaccine. Pediatrics. 1998;101:129–133
  38. Choo PW, Donahue JG, Manson JE, Platt R. The epidemiology of varicella and its complications. J Infect Dis. 1995;172:706–712
  39. Brisson M, Edmunds WJ, Law B. Epidemiology of varicella zoster infection in Canada and the United Kingdom. Epidemiol Infect. 2001;127:305–314
  40. Galil K, Lee B, Strine T, Carraher C, Baughman A, Eaton M, et al. Outbreak of varicella at a day-care center despite vaccination. N Engl J Med. 2002;347:1909–1915
  41. Bramley C. In: Severe complications of varicella. vol. 11:British Paediatric Surveillance Unit (BPSU); 2003 (Dec);p. 2
  42. MacDonald NE, Morris RF, Beaudry PH. Varicella in children with cystic fibrosis. Pediatr Infect Dis J. 1987;6:414–416
  43. Ong EL, Mulvenna P, Webb KA. Varicella-zoster infection in adults with cystic fibrosis: role of acyclovir. Scand J Infect Dis. 1991;23:283–285
  44. Gogos CA, Bassaris HP, Vageakis AG. Varicella pneumonia in adults. A review of pulmonary manifestations, risk factors and treatment. Respiration. 1992;59:339–343
  45. Pugh RN, Omar RI, Hossain MM. Varicella infection and pneumonia among adults. Int J Infect Dis. 1998;2:205–210
  46. Mer M, Richards GA. Corticosteroids in life-threatening varicella pneumonia. Chest. 1998;114:426–431
  47. Mohsen AH, McKendrick M. Varicella pneumonia in adults. Eur Respir J. 2003;21:886–891
  48. Miller E, Vurdien J, Farrington P. Shift in age in chickenpox. Lancet. 1993;341:308–309
  49. Koc Y, Miller KB, Scheinkein DP, Griffith J, Akhtar M, DesJardin J, et al. Varicella-zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors and clinical outcome. Biol Blood Marrow Transplant. 2000;6:44–49
  50. Pandya A, Wasfy S, Hebert D, Allen UD. Varicella-zoster infection in pediatric solid-organ transplant recipients: a hospital-based study in the prevaricella vaccine era. Pediatr Transplant. 2001;5:153–159
  51. Simultaneous administration of varicella vaccine and other recommended childhood vaccines–United States, 1995–1999. MMWR Morb Mortal Wkly Rep. 2001;50:1058–1061
  52. Levin MJ, Smith JG, Kaufhold RM, Barber D, Hayward AR, Chan CY, et al. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-hose VZV vaccine. J Infect Dis. 2003;188:1336–1344
  53. Thiry N, Beutels P, Shkedy Z, Vranckx R, Vandermeulen C, Van Der Wielen M, et al. The seroepidemiology of primary varicella-zoster virus infection in Flanders (Belgium). Eur J Pediatr. 2002;161:588–593
  54. Vessey SJR, Chan CY, Kuter BJ, Kaplan KM, Waters M, Kutzler DP, et al. Childhood vaccination against varicella: persistence of antibody, duration of protection, and vaccine efficacy. J Pediatr. 2001;139:297–304
  55. Gershon AA. Varicella vaccine—are two doses better than one?. N Engl J Med. 2002;347:1962–1963
  56. Hiatt PW, Grace SC, Kozinetz CA, Helioui Raboudi S, Treece DG, Taber LH, et al. Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis. Pediatrics. 1999;103:619–626
  57. Peterson NT, Hoiby N, Mordhorst CH, Lind K, Flensborg EW, Bruun B. Respiratory infections in cystic fibrosis patients caused by virus, chlamydia and mycoplasma—possible synergism with Pseudomonas aeruginosa. Acta Paediatr Scand. 1981;70:623–628
  58. Pribble CG, Black PG, Bosso JA, Turner RB. Clinical manifestations of exacerbations of cystic fibrosis associated with nonbacterial infections. J Paediatr. 1990;117:200–204
  59. Ferson MJ, Morton JR, Robertson PW. Impact of influenza on morbidity in children with cystic fibrosis. J Paediatr Child Health. 1991;27:308–311
  60. Ramsey BW, Gore EJ, Smith AL, Cooney MK, Redding GJ, Foy H. The effect of respiratory viral infections on patients with cystic fibrosis. Am J Dis Child. 1989;143:662–668
  61. Izurieta HS, Thompson WW, Kramarz P, Shay DK, Davis RL, DeStefano F, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med. 2000;342:232–239
  62. Neuzil KM, Mellen BG, Wright PF, Mitchel EF, Griffin MR. The effect of influenza on hospitalizations, outpatient visits and courses of antibiotics in children. N Engl J Med. 2000;342:225–231
  63. Glezen WP. Influenza and hospitalizations in children. N Engl J Med. 2000;342:1752–1753
  64. CDC . Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2002;51:1–31
  65. Wareing MD, Tannock GA. Influenza update: vaccine development and clinical trials. Curr Opin Pulm Med. 2002;8:209–213
  66. Ong EL, Bilton D, Abott J, Webb AK, McCartney RA, Caul EO. Influenza vaccination in adults with cystic fibrosis. BMJ. 1991;303:557
  67. Gruber WC, Campbell PW, Thompson JM, Reed GW, Roberts B, Wright PF. Comparison of live attenuated and inactivated influenza vaccines in cystic fibrosis patients and their families: results of a 3-year study. J Infect Dis. 1994;169:241–247
  68. Conway SP, Simmonds EJ, Littlewood JM. Acute severe deterioration in cystic fibrosis associated with influenza A virus infection. Thorax. 1992;47:112–114
  69. Schaad UB, Bühlmann U, Burger R, Ruedeberg A, Wilder-Smith A, Rutishauser M, et al. Comparison of immunogenicity and safety of a virosome influenza vaccine with those of a subunit vaccine in paediatric patients with cystic fibrosis. Antimicrob Agents Chemother. 2000;44:1163–1167
  70. Stephenson I, Nicholson KG. Influenza: vaccination and treatment. Eur Respir J. 2001;17:1282–1293
  71. Örtqvist A. Pneumococcal vaccination: current and future issues. Eur Respir J. 2001;18:184–195
  72. Lahiri T, Waltz DA. Pre-immunization anti-pneumococcal antibody levels are protective in a majority of patients with cystic fibrosis. Pediatrics. 2001;108:e62
  73. Amber IJ, Gilbert EM, Schiffman G, Jacobson JA. Increased risk of pneumococcal infections in cardiac transplant recipients. Transplantation. 1990;122–125
  74. Linneman CC, First MR. Risk of pneumococcal infection in renal transplant patients. JAMA. 1979;241:2619–2621
  75. American Academy of Pediatrics . Pneumococcal infections. In:  Pickering LK editors. Red book: report of the committee on infectious diseases. vol. 452:Elk Grove Village, IL: American Academy of Pediatrics; 2000;p. 458–459
  76. Linneman CC, First R, Schiffman G. Revaccination of renal transplant and hemodialysis recipients with pneumococcal vaccine. Arch Intern Med. 1986;146:1554–1556
  77. Musher DM, Luchi M, Watson DA, Hamilton R, Baughn RE. Pneumococcal polysaccharide vaccine in young adults and older bronchitics: determination of IgG responses by ELISA and the effect of adsorption of serum with non-type specific cell wall polysaccharide. J Infect Dis. 1990;161:728–735
  78. Musher DM, Groover JE, Rowland JM, Watson DA, Struewing JB, Baughn RE, et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae: prevalence, persistence, and response to revaccination. Clin Infect Dis. 1993;17:66–73
  79. Rubins JB, Puri AK, Loch J, Charboneau D, MacDonald R, Opstad N, et al. Magnitude, duration, quality and function of pneumococcal vaccine responses in elderly adults. J Infect Dis. 1998;178:431–440
  80. Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V, Margolis A, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med. 1991;325:1453–1460
  81. Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Pneumococcal polysaccharide vaccine efficacy: an evaluation of current recommendations. JAMA. 1993;270:1826–1831
  82. Fine MJ, Smith MA, Carson CA, Meffe F, Sankey SS, Weissfeld LA, et al. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. Arch Intern Med. 1994;154:2666–2677
  83. Sorensen RU, Leiva LE, Giangrosso PA, Butler B, Javier FC, Sacerdote DM, et al. Response to a heptavalent conjugate Streptococcus pneumoniae vaccine in children with recurrent infections who are unresponsive to the polysaccharide vaccine. Pediatr Infect Dis. 1998;17:685–691
  84. Shinefield HR, Black S. Efficacy of pneumococcal conjugate vaccines in large scale field trials. Pediatr Infect Dis J. 2000;19:394–397
  85. Malfroot A, De Schutter I, Mascart F, Crusiaux A, Dab I. Indication of pneumococcal vaccination in CF patients. Eur Respir J. 2001;118(Suppl. 23):539s
  86. Stovall SH, Ainley KA, Mason EO, Tucker NC, Frazier EA, Parker JG, et al. Invasive pneumococcal infection in pediatric cardiac transplant patients. Pediatr Infect Dis J. 2001;20:946–950
  87. Von Kries R, Siedler A, Schmitt HJ, Reinert RR. Proportion of invasive pneumococcal infections in German children preventable by pneumococcal conjugate vaccines. Clin Infect Dis. 2000;31:482–487
  88. Eskola J, Kayhty H, Takala AK, Peltola H, Ronnberg PR, Kela E, et al. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. N Engl J Med. 1990;323:1381–1387
  89. De Schutter I, Dab I, Pierard D, Amarales L, Malfroot A, Kim KW. Haemophilus influenzae in the lower respiratory tract of infants and children. Eur Respir J. 1999;14(Suppl. 30):155s
  90. Breukels MA, Jol-van der Zijde E, van Tol MJ, Rijkers GT. Concentration and avidity of anti-Haemophilus influenzae type b (Hib) antibodies in serum samples obtained from patients for whom Hib vaccination failed. Clin Infect Dis. 2002;34:191–197
  91. McVernon J, Andrews N, Slack MPE, Ramsey ME. Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet. 2003;361:1521–1523
  92. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against menigococcal serogroup C disease in the UK: a success story. Vaccine. 2001;20(Suppl. 1):S58–S67
  93. Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med. 2001;344:1917–1928
  94. Dudas RA, Karron RA. Respiratory syncytial virus vaccines. Clin Microbiol Rev. 1998;11:430–439
  95. Piedra PA. Respiratory syncytial virus vaccines: recent developments. Pediatr Infect Dis J. 2000;19:805–808
  96. Stein RT, Sherill D, Morgan WL. RSV in early life and risk of wheeze and allergy by age 13. Lancet. 1999;354:541–545
  97. Lenney W. RSV disease—is there a role for prevention?. Respir Med. 2001;95:170–172
  98. Walsh EE, Falsey A, Hennessey P. Respiratory syncytial and other virus infections in persons with chronic cardiopulmonary disease. Am J Respir Crit Care Med. 1999;160:791–795
  99. Hiatt PW, Taber L, Raboudi S, Treece D. Respiratory viral infection and pulmonary function in infants with cystic fibrosis. Am Rev Respir Dis. 1992;145:A115
  100. Smyth AR, Smyth AL, Tong CYW, Hart CA, Heaf DP. Effect of respiratory virus infections including rhinovirus on clinical status in cystic fibrosis. Arch Dis Child. 1995;73:117–120
  101. Johansen HK, Høiby N. Seasonal onset of initial colonisation and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis. Thorax. 1992;47:109–111
  102. Wang EL, Prober CG, Manson B, Corey M, Levison H. Association of respiratory viral infection with pulmonary deterioration in patients with cystic fibrosis. N Engl J Med. 1984;311:1653–1658
  103. Armstrong D, Grimwood K, Carlin JB, Carzino R, Hull J, Olinsky A, et al. Severe viral respiratory infections in infants with cystic fibrosis. Pediatr Pulmonol. 1998;26:371–379
  104. Abman SH, Ogle JW, Butler-Simon N, Rumack C, Accurso F. Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis. J Pediatr. 1988;113:826–830
  105. Heinzl B, Eber E, Oberwaldner B, Haas G, Zach MS. Effects of inhaled gentamycin prophylaxis on acquisition of Pseudomonas aeruginosa in children with cystic fibrosis: a pilot study. Pediatr Pulmonol. 2002;33:32–37
  106. Groothuis JR, Simoes EAF, Levin MJ, Hall CB, Long CE, Rodriguez J, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med. 1993;329:1524–1530
  107. Sorrentino M, Powers T. Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. Pediatr Infect Dis J. 2000;19:1068–1071
  108. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969;89:422–434
  109. Karron RA, Wright PF, Crowe JE, Clements-Mann M-L, Thompsom J, Makhene M, et al. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J Infect Dis. 1997;176:1428–1436
  110. Englund J, Glezen WP, Piedra PA. Maternal immunization against viral disease. Vaccine. 1998;16:1456–1463
  111. Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic fibrosis. Clin Microbiol Rev. 2002;15:194–222
  112. Tummler B, Bosshammer J, Breitenstein S, Brockhausen I, Gudowius P, Herrmann C, et al. Infections with Pseudomonas aeruginosa in patients with cystic fibrosis. Behring-Inst-Mitt. 1997;98:249–255
  113. Holder IA. Pseudomonas vaccination and immunotherapy: an overview. J Burn Care Rehabil. 2001;5:311–320
  114. Keogan MT, Johansen HK. Vaccines for preventing infection with Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev. 2000;2:[CD001399]

PII: S1569-1993(05)00032-9

doi: 10.1016/j.jcf.2004.10.003

Journal of Cystic Fibrosis
Volume 4, Issue 2 , Pages 77-87 , May 2005

Article Tools